Replies to post #58401 on NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

Do you not understand the king's English?
Here is it is one more time Dr Prins verbatim:

30:37
I think that in conclusion immunotherapy is an exciting new field
It may likely be relevant for glioblastoma in the near future.
Although there are a lot of on going clinical trials going on right now
Not all glioblastomas are likely to be sensitive. I think t
There are some subtypes ahhh more likely to respond to an immune based therapy
We got to learn how to predict.
Some of these patients are likely to have incomplete tumor resections from the clinical side.
This is hard to treat because of the adaptive immune resistance that develops and combinatorial strategies are probably likely to be important.
The identification of patient specific neoantigens I am sure is going to be relevant.
The ability to be able to do it in a straight forward fashion that you can do it to make a difference for patients is really what the future is going to hold.
31:38

If you are going to ding me for not quoting verbatim then quote something verbatim that support your point

[CherryTree1]

Yes we are all a bit riled up by this. It is hard not to believe we are sitting on the precipice of really REALY good news:
(1) DVAX-L Approval for Mesenchyma Subgroup patients (at minimum)
(2) Joint new trial with Merck & BMS for DVAX with PDL1 inhibiots
Again HEE HA . . . HIP HIP . . .
Fasten your seat-belt Dorothea cause Kansas is about to go bye-bye